Abstract
The authors assessed the prevalence of headaches following extended-release dipyridamole/aspirin combination (DAC), and the efficacy of acetaminophen in the treatment of these headaches. Following DAC, 38.7% of the participants developed headaches. The headaches were self-limited (69.4% placebo efficacy in 2 hours) and the incidence markedly declined over time. Acetaminophen was no more effective than placebo in the acute and preemptive treatment of these headaches.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetaminophen / therapeutic use*
-
Aged
-
Analgesics, Non-Narcotic / therapeutic use*
-
Aspirin / administration & dosage
-
Aspirin / adverse effects*
-
Dipyridamole / administration & dosage
-
Dipyridamole / adverse effects*
-
Drug Combinations
-
Female
-
Headache / chemically induced
-
Headache / drug therapy*
-
Headache / prevention & control
-
Humans
-
Incidence
-
Male
-
Middle Aged
-
Prevalence
-
Remission, Spontaneous
-
Risk
-
Treatment Failure
Substances
-
Analgesics, Non-Narcotic
-
Drug Combinations
-
Acetaminophen
-
Dipyridamole
-
Aspirin